News blog
Medgenics Inc
- BY: Andrew Hore |
- POSTED: 27/03/2009 |
Medgenics Inc has revealed positive trial news for its EPODURE treatment.
The shares rose 0.125p to 3.25p a share, which values Israel-based Medgenics at £3.98m. More potential partners have become interested in the technology.
EPODURE produces EPO (erythro-protein) to treat anaemia.
The first two patients treated with a single dose of EPODURE have maintained their haemoglobin levels within target levels for five months. They have not needed any EPO injections, which are normally required three times a week. That equates to a dozen injections each month.
A total of seven patients have been treated and six received the treatment more than one month ago. The latest patient has been given a higher dose. There are no reported adverse effects for any of the patients.
The trial will be widened to include dialysis patients as well as pre-dialysis patients.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|